MOA Life Plus Co. Ltd.

A142760

KR7142760008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
2,275 ^KRW	-1.73%		-13.83%	+6.81%

15/04	Bioleaders Corporation announced that it has received KRW 10 billion in funding from Moadata Co., Ltd.	CI
29/03	Bioleaders Corporation announced that it has received KRW 15 billion in funding	CI

Bioleaders Corporation announced that it has received KRW 13 billion in funding from Blash Asset Management Co., Ltd, Tiger Asset Management Discretionary Investment Co., Ltd., and other investors

December 01, 2021

On December 1, 2021, Bioleaders Corporation closed the transaction. The company has received its second and final tranche. The company has issued series 9 bonds for gross proceeds of KRW 8,000,000,000.

Latest news about MOA Life Plus Co. Ltd.

Bioleaders Corporation announced that it has received KRW 10 billion in funding from Moadata Co., Ltd.	15/04	CI
Bioleaders Corporation announced that it has received KRW 15 billion in funding	29/03	CI
Youngchul Park completed the acquisition of 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation.	28/03	CI
Moadata Co., Ltd. completed the acquisition of 6.95% stake in Bioleaders Corporation from Youngchul Park.	28/03	CI
Bioleaders Corporation announced that it expects to receive KRW 15 billion in funding	14/03	CI
Moadata Co., Ltd. agreed to acquire a 6.95% stake in Bioleaders Corporation from Youngchul Park for KRW 15.3 billion	13/03	CI
Bioleaders Corporation announced that it expects to receive KRW 10 billion in funding from Moadata Co., Ltd.	12/03	CI
Youngchul Park agreed to acquire 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation for KRW 9.3 billion.	12/03	CI
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	02/01	CI
An unknown buyer agreed to acquire 20.25052% stake in Anyone F&C Co., Ltd. from Bioleaders Corporation for KRW9.9 billion.	29/12	CI
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	29/12	CI
Bioleaders Corporation(KOSDAQ:A142760) dropped from S&P Global BMI Index	18/23/18	CI
Bioleaders Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Next Bt Co., Ltd. announced that it has received KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors	01/21/01	CI
Bioleaders Corporation announced that it has received KRW 13 billion in funding from Blash Asset Management Co., Ltd, Tiger Asset Management Discretionary Investment Co., Ltd., and other investors	01/21/01	CI
Bioleaders Corporation announced that it has received KRW 8 billion in funding	01/21/01	CI
Bioleaders Corporation announced that it expects to receive KRW 8 billion in funding from Blash Asset Management Co., Ltd, Tiger Asset Management Discretionary Investment Co., Ltd., and other investors	29/21/29	CI
Bioleaders Corporation announced that it expects to receive KRW 8 billion in funding	29/21/29	CI
Next Bt Co., Ltd. announced that it expects to receive KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors	29/21/29	CI
Bioleaders Corporation announced that it has received KRW 13 billion in funding from C-Square Asset Management, A One Asset Management Co., Ltd, Bluetech Asset Management Co., Ltd., Mirae Asset Daewoo Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm and other investors	18/21/18	CI
Bioleaders Corporation announced that it has received KRW 10.0000159 billion in funding from Asset One Asset Management	18/21/18	CI
Bioleaders Corporation announced that it expects to receive KRW 13 billion in funding from C-Square Asset Management, A One Asset Management Co., Ltd, Bluetech Asset Management Co., Ltd., Mirae Asset Daewoo Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm and other investors	16/21/16	CI
Bioleaders Corporation announced that it expects to receive KRW 10.0000159 billion in funding from Asset One Asset Management	09/21/09	CI
Bioleaders Corporation announced that it has received KRW 7.1 billion in funding	26/19/26	CI
Bioleaders Corporation announced that it has received KRW 4 billion in funding from Hana Financial Investment Co., Ltd., Meritz Securities Co., Ltd. and another investor	29/19/29	CI

Chart MOA Life Plus Co. Ltd.

Duration

Period

More charts

Company Profile

Moa Life Plus, formerly BL Corp, is a Korea-based company primarily engaged in the research and development of biotechnology and biopharmaceuticals. The Company is engaged in the manufacture and sale of health functional foods and functional cosmetics. In addition, the Company is engaged in the distribution of pharmaceuticals and medical supplies. The Company is engaged in the development of cervical cancer treatment, anticancer drugs and other products.

Sector

Pharmaceuticals

Calendar

14/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MOA LIFE PLUS CO. LTD.	+6.81%	62.78M
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+32.39%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.50%	240B
NOVARTIS AG	+9.56%	209B
ROCHE HOLDING AG	-9.04%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals

MOA Life Plus Co. Ltd.

Equities

A142760

KR7142760008

Pharmaceuticals

Bioleaders Corporation announced that it has received KRW 13 billion in funding from Blash Asset Management Co., Ltd, Tiger Asset Management Discretionary Investment Co., Ltd., and other investors

Latest news about MOA Life Plus Co. Ltd.

Chart MOA Life Plus Co. Ltd.

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals